No money for UK biotech

The precarious position of the UK’s life sciences sector is underlined by fundraising failures among 295 of its members.
01 Apr 2009

More money than sense

Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.
15 Oct 2008

Biotech hit by credit crunch

As stock markets turn their backs on the high-risk sectors, France Biotech’s annual survey reveals the depths to which investment has fallen.
08 Oct 2008